Editorial

DOI: 10.4244/EIJ-E-22-00026

Low urine pH: a new marker for contrast-associated acute kidney injury?

Carlo Briguori1, MD, PhD; Giuseppina Roscigno2, PhD

Intravenous hydration is the standard of care for preventing contrast-associated acute kidney injury (CA-AKI) in patients undergoing invasive cardiovascular procedures12. However, the type of solution, the volume and the timing of administration are still a matter of debate. Intravascular volume expansion is usually accomplished by the administration of isotonic saline. Several hydration protocols have been reported and recommended (Table 1).

Sodium bicarbonate has been proposed as an alternative solution to prevent CA-AKI3. One potential mechanism of kidney protection is the alkalinisation of the renal tubular fluid and the scavenging of reactive species generated from nitric oxide. Free radical formation is promoted by an acidic environment typical of tubular urine but is inhibited by the higher pH of normal extracellular fluid. Sodium bicarbonate has been compared with isotonic saline in several randomised trials with conflicting results3456. The most definitive data are from the Prevention of Serious Adverse Events Following Angiography (PRESERVE) randomised trial, which included 4,993 high-risk patients undergoing scheduled angiography and found that both treatments were associated with similar outcomes7.

In the current issue of EuroIntervention, Lombardi et al report on the PrevenTion of contrast-inducEd nephropAThy with urinE alkalinisation (TEATE) prospective, randomised, open-label trial to test the hypothesis that an alkaline urine status with either oral or intravenous (i.v.) bicarbonate on top of hydration alone prevents CA-AKI8. The authors compared 1) saline hydration alone; 2) i.v. bicarbonate; and 3) oral bicarbonate, in patients with chronic kidney disease scheduled for the intra-arterial contrast media (CM) administration. The primary endpoint was the incidence of CA-AKI according to alkaline urine status achieved immediately before angiography. Secondary endpoints were the mean change in urine pH up to the time of angiography and the incidence of CA-AKI in the 3 groups. Patients achieving a pH >6 before angiography had significantly lower incidences of CA-AKI compared with the others (odds ratio 0.48, 95% confidence interval: 0.25-0.90; p=0.023). The proportion of patients achieving a pH >6 was significantly higher in the i.v. and oral bicarbonate groups compared with hydration alone. The incidence of CA-AKI, however, was not significantly different in the 3 treatment arms.

The authors conclude that urinary pH before CM administration is an inverse correlate of CA-AKI incidence, and bicarbonate is superior to hydration alone in achieving urinary alkalinisation. However, bicarbonate did not reduce the incidence of CA-AKI. Although being a confirmatory study, which reaffirms the lack of superiority of sodium bicarbonate solution versus sodium chloride solution in CA-AKI prevention, the TEATE trial emphasises an important new concept in the field of CA-AKI prevention. Sodium bicarbonate solution might be superior to normal saline only in patients with a baseline urine pH <6. The pH of urine ranges from 4.5 to 8, depending upon the systemic acid-base balance. The median pH of human 24-hour urine is ∼69. A low urine pH has been found as a predictor of chronic kidney disease10. In the REMEDIAL trial, baseline urine pH was <6 in approximately 17% of patients5. Further studies that only include patients with a baseline urine pH <6 are needed to clarify this concept.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.


References

Volume 18 Number 7
Sep 20, 2022
Volume 18 Number 7
View full issue


Key metrics

On the same subject

INTERVENTIONAL FLASHLIGHT

10.4244/EIJ-D-17-00774 Oct 19, 2018
Ultra-low contrast percutaneous coronary intervention in patients with severe chronic kidney disease
Azzalini L et al
free

CLINICAL RESEARCH

10.4244/EIJ-D-17-00308 Jun 14, 2018
Incidence and predictors of acute kidney injury in patients undergoing proximal protected carotid artery stenting
Pucciarelli A et al
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved